• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Respir Med . A prospective evaluation of lung function at three and six months in patients with previous SARS-COV-2 pneumonia

tetano

Editor, Senior Moderator
Respir Med


. 2021 Jul 10;186:106541.
doi: 10.1016/j.rmed.2021.106541. Online ahead of print.
A prospective evaluation of lung function at three and six months in patients with previous SARS-COV-2 pneumonia


Nicla Orzes[SUP] 1 [/SUP], Laura Pini[SUP] 2 [/SUP], Guido Levi[SUP] 1 [/SUP], Silvia Uccelli[SUP] 1 [/SUP], Francesca Cettolo[SUP] 1 [/SUP], Claudio Tantucci[SUP] 3 [/SUP]



Affiliations

Abstract

Objective: This study investigated the consequences of Coronavirus Disease 2019 (COVID-19) pneumonia on lung function in the first 6 months after hospital discharge.
Methods: A prospective lung function assessment in SARS-CoV2 patients with COVID-19 pneumonia, hospitalized between March and April 2020, was conducted with spirometry measurements including lung volumes, mainly total lung capacity (TLC), lung diffusion capacity for carbon monoxide (DL[SUB]CO[/SUB]) collected at 3 months after hospital discharge. Patients with restrictive ventilatory defect or impaired DL[SUB]CO[/SUB] or both were re-evaluated at 6 months with global spirometry and chest HRCT scan.
Results: Among 40 consecutive patients, 19 (48%) had normal pulmonary functional tests (group A), and 21 (52%) showed residual lung function abnormalities at 3 months after hospital discharge (group B). In group B, 4 patients (19%) had only loss of lung volume as shown by TLC reduction (group 1), 13 patients (62%) had decreased both TLC and DL[SUB]CO[/SUB] (group 2), and 4 patients (19%) had isolated reduction in DL[SUB]CO[/SUB] (group 3). At 6-month follow-up in group 1, although all patients improved, only one normalized total lung capacity (TLC). In group 2, TLC and DL[SUB]CO[/SUB] increased significantly (p < 0.01), but only 3 patients reached normal values. In group 3, DL[SUB]CO[/SUB] improved for most patients, normalizing in 50% of them. At 6-months significant correlations between an internal-built chest HRCT scan severity score and TLC (r[SUP]2[/SUP] = 0.33; p < 0.01) and DL[SUB]CO[/SUB] (r[SUP]2[/SUP] = 0.32; p < 0.01) were found.
Conclusions: Nearly 50% of patients recovered in the post-critical phase. Most of those with abnormal pulmonary function tests at 3 months improved subsequently, but only another 29% (6 out of 21) reached normal values at 6 months. These results indicate that lung function spontaneous recovery is faster at first and occurs more slowly thereafter, leaving more than one third (15 out of 40) of patients with abnormal lung function tests at 6 months.

Keywords: COVID-19; Lung function; Pneumonia; SARS-CoV2; Spirometry.
 
Back
Top Bottom